Our Mission
We develop new molecular imaging and theranostic probes for better detection and therapy in patients with cancer. Specializing in emission tomography (PET), radionuclide therapies, and hyperpolarized 13C magnetic resonance imaging, our lab members integrate new chemistry, chemical biology, imaging, and clinical methods to create new innovations and methodologies that improve patient care.
Research
Our research team focuses on PET/CT and SPECT/CT imaging, radionuclide therapies, and hyperpolarized 13C MRI. We develop molecular imaging and theranostic probes, including immunoPET agents for prostate cancer and CD46-targeted therapies for multiple myeloma, as well as tumor-targeted drug delivery and pH imaging to improve prostate cancer detection, all focused on enhancing patient outcomes.
